Our deeply established relationships in the pharmaceutical industry makes us the unrivalled advisor for your cross-border transaction
The Results Healthcare team is dedicated to advising large pharma corporates and smaller biotech businesses as well as companies which provide direct technical services to these companies, on bringing innovative drugs and treatments to market for the benefit of patients and society. Our extensive international relationships in the pharma and biotech industry sets us apart from our competitors and our focus on supporting our clients in their strategic initiatives to create new business models, drive external growth and increase profitability makes us the unrivalled advisor for the sector.
Contract research organisations (CROs) and contract manufacturing organisations (CMOs) are among the strongest growth sectors of the pharmaceutical industry, with many firms experiencing double-digit annual growth. We work with CROs and CMOs in organisation asset restructuring and building core divisions through M&A activity.
Our team has a strong track-record having advised on some of the most important deals in the space including INC Research on signing its definitive merger agreement with inVentiv, GHO Capital, on its acquisition of Sterling Pharma Solutions and Linguamatics on its acquisition by IQVIA.
A combination of our deep sector knowledge and long-standing industry relationships enables us to get the best outcomes for our clients.
The medical technology sector (medtech) has long benefited from rising demand from demographic factors and the rapid expansion of international markets. More recently, innovation has created the opportunity for step change growth, with the advent of ‘smart devices’ and the introduction of digital technology to the bedside and the operating theatre.
Results Healthcare, with our international capability and deep understanding of healthcare systems in multiple territories, is ideally positioned to support clients to make the most of the growth opportunities in the manufacture, supply and distribution of medical equipment and consumables.
18 Mar 2021
Results Healthcare is delighted to have acted as exclusive advisor to Ajinomoto Bio-Pharma Services, a fully integrated contract development and…
18 Jan 2021
Results Healthcare is delighted to have acted as the exclusive advisor to MSD, a leading global biopharmaceutical company, on the…
18 Mar 2021
M&A and valuations in the CRO sector – March 2021 The level of impact that Covid-19 has had on M&A…
26 Feb 2021
Results Healthcare has advised SQN Clinical on its acquisition by Veristat
Results Healthcare is pleased to announce that it has advised SQN Clinical, one of the largest data focused specialty contract…
15 Nov 2019
Private equity appetite for the life sciences sector
Private equity firms are finding more creative ways to increase their investment in the life sciences sector. The life sciences…
Subscribe to receive our latest sector-specific research on M&A activity and fundraisings:
21 Apr 2021 - 3pm-4pm (BST - UK), 10am-11am (ET - NY)
The next chapter: Changing market dynamics in commercialisation and medical communications
The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw…